• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    HC Wainwright resumed coverage on Innate Pharma with a new price target

    2/4/21 4:38:12 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IPHA alert in real time by email
    HC Wainwright resumed coverage of Innate Pharma with a rating of Buy and set a new price target of $13.00
    Get the next $IPHA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IPHA

    DatePrice TargetRatingAnalyst
    9/18/2025Buy → Neutral
    H.C. Wainwright
    9/18/2025Outperform → Market Perform
    Leerink Partners
    7/28/2025$8.00Buy
    BTIG Research
    9/17/2021$7.00 → $9.00Outperform
    SVB Leerink
    9/3/2021$7.00Mkt Perform → Outperform
    SVB Leerink
    9/3/2021Market Perform → Outperform
    SVB Leerink
    9/2/2021Market Perform → Outperform
    SVB Leerink
    More analyst ratings

    $IPHA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Innate Pharma Reports First Half 2025 Business Update and Financial Results

    IPH4502 Nectin-4 ADC Phase 1 enrollment progressing well: Preclinical update and Trial In Progress presented at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting. Lacutamab BTD and Phase 3 preparation: FDA Breakthrough Therapy Designation (BTD) in February 2025 based on long-term follow-up data from the TELLOMAK clinical study presented at ASCO Annual Meeting 2025. Preparation of the confirmatory Phase 3 trial protocol is close to completion, following discussions with the FDA and EMA. Monalizumab: AstraZeneca Phase 3 PACIFIC-9 enrollment is completed and high level read-out is expected in H2 2026. Strategic focus: Innate Pharma plans to prioritize its investment in what it

    9/17/25 1:00:00 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

    Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that Frédéric Lombard, Chief financial Officer of the Company, will participate in the 25th edition of the European Midcap Event being held from September 30 to October 1, 2025 in Paris, France. The European Midcap Event is a key gathering that brings together institutional investors and listed companies to foster strategic meetings and financing opportunities. This flagship event provides a unique platform to engage with the European financial community. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer p

    9/15/25 1:00:00 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

    Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Wednesday, September 17, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2025. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Details for the Virtual Event The live webcast will be available at the following link: https://events.q4inc.com/attende

    9/10/25 4:30:00 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPHA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Innate Pharma downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Innate Pharma from Buy to Neutral

    9/18/25 12:37:06 PM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Innate Pharma downgraded by Leerink Partners

    Leerink Partners downgraded Innate Pharma from Outperform to Market Perform

    9/18/25 8:35:18 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BTIG Research initiated coverage on Innate Pharma with a new price target

    BTIG Research initiated coverage of Innate Pharma with a rating of Buy and set a new price target of $8.00

    7/28/25 8:59:02 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPHA
    SEC Filings

    View All

    SEC Form 6-K filed by Innate Pharma S.A. ADS

    6-K - Innate Pharma SA (0001598599) (Filer)

    9/17/25 6:40:58 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Innate Pharma S.A. ADS

    6-K - Innate Pharma SA (0001598599) (Filer)

    9/17/25 6:24:13 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Innate Pharma S.A. ADS

    6-K - Innate Pharma SA (0001598599) (Filer)

    9/15/25 6:00:44 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPHA
    Leadership Updates

    Live Leadership Updates

    View All

    Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

    Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors Irina Staatz-Granzer, current Chairwoman of the Supervisory board would be appointed Chairwoman of the board of Directors Jonathan Dickinson, current Chairman of the Executive board would be appointed Chief Executive Officer and named to the board of Directors Two new members would join the board of Directors Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced it will propose to its Annual General Meeting taking place on May 22, 2025, to move from

    4/16/25 1:00:00 AM ET
    $AUTL
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board

    Jonathan Dickinson joins Innate on November 1 and brings broad experience from leadership roles in biotech and big pharma Current interim CEO and co-founder Hervé Brailly will support the transition Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that its supervisory Board has appointed Jonathan Dickinson as the Company's new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process. Jonathan Dickinson most recently served as Executive Vice President and General Manager, Europe

    10/14/24 1:00:00 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board

    Two new Executive Board members appointed under recently announced interim CEO, Hervé Brailly Yannis Morel broadens remit to Chief Operating Officer Sonia Quaratino, Chief Medical Officer, appointed to the Executive Board Arvind Sood joins the Company and is appointed Executive Vice President, President of US Operations and to the Executive Board Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that it has strengthened the Company's leadership and corporate governance with the appointment of two new Executive Board members. Arvind Sood, Executive Vice President (EVP), President of US Operations, Dr Sonia Quaratino, EVP, Ch

    1/4/24 12:59:00 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPHA
    Financials

    Live finance-specific insights

    View All

    Innate Pharma Reports First Half 2025 Business Update and Financial Results

    IPH4502 Nectin-4 ADC Phase 1 enrollment progressing well: Preclinical update and Trial In Progress presented at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting. Lacutamab BTD and Phase 3 preparation: FDA Breakthrough Therapy Designation (BTD) in February 2025 based on long-term follow-up data from the TELLOMAK clinical study presented at ASCO Annual Meeting 2025. Preparation of the confirmatory Phase 3 trial protocol is close to completion, following discussions with the FDA and EMA. Monalizumab: AstraZeneca Phase 3 PACIFIC-9 enrollment is completed and high level read-out is expected in H2 2026. Strategic focus: Innate Pharma plans to prioritize its investment in what it

    9/17/25 1:00:00 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

    Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Wednesday, September 17, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2025. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Details for the Virtual Event The live webcast will be available at the following link: https://events.q4inc.com/attende

    9/10/25 4:30:00 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

    €15 million investment by Sanofi, in addition to the ongoing partnership including the development of BCMA targeting ANKET® program in autoimmune indications First patient dosed in a Phase 1 study for IPH4502, Nectin-4 ADC in patients with selected advanced solid tumors. Presentations at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome; long term follow up data from TELLOMAK Phase 2 to be presented at ASCO Annual Meeting 2025 Cash position of €72.5 million1 as of March 31, 2025, excluding the €15 million received from Sanofi, with a cash horizon to mid 2026 Conference call to b

    5/13/25 1:00:00 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPHA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Innate Pharma S.A. ADS (Amendment)

    SC 13D/A - Innate Pharma SA (0001598599) (Subject)

    12/6/22 11:52:53 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Innate Pharma S.A. ADS (Amendment)

    SC 13D/A - Innate Pharma SA (0001598599) (Subject)

    10/21/22 12:58:48 PM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed

    SC 13D - Innate Pharma SA (0001598599) (Subject)

    2/12/21 2:35:54 PM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care